Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Hyperpolarised MR technologies and molecular probes as alternatives for conventional metal-containing contrast agents for MRI examinations

Project description

Safer diagnostic agents for MRI

Contrast-enhanced magnetic resonance imaging (MRI) is an important and versatile medical diagnostics technique, particularly for cancers. Warnings have been issued against Gadolinium (Gd)-based contrast agents (GBCAs), which are routinely employed during MRI diagnostic procedures, due to health concerns about Gd accumulation in the human body. The EU-funded AlternativesToGd project aims to develop metal-free hyperpolarised (HP) metabolic CAs to enable molecular imaging and monitor enzymatic conversions with very high sensitivity. A major challenge for researchers is overcoming the short lifetime of HP states in these CAs. The team will investigate three ground-breaking HP techniques to maximise HP lifetime and achieve unprecedented sensitivity in contrast-enhanced MRI diagnostics with CAs that are safe, non-toxic and completely eliminated from the body after the procedure.

Objective

Recently, the European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA) recommended suspension and warning labels for Gadolinium (Gd)-bearing CAs (GBCA) used in magnetic resonance imaging (MRI). This decision, although made in the absence of any clinical evidence, relates to potential major health concerns resulting from long-term accumulation of Gd containing species in patients’ bodies. This sends a clear message that we need to carefully consider the necessity of each contrast injection in individuals undergoing an MRI scan. However, for a number of diagnostic procedures, such as tumour characterisation, the use of a CA is often essential. The accumulation of Gd in different organs (including the brain) and GBCA-related diseases requires the scientific community to seek radically new alternatives. The AlternativesToGd vision is to identify and validate radically new compounds and technologies as alternatives to GBCAs. The new compounds and technologies developed in this proposal will be tested in animal models of disease and the most promising ones selected for further clinical development. The expected outcomes should radically impact the field, likely leading to a paradigm shift in MR-based diagnosis and thus being highly beneficial to society. The AlternativesToGd consortium will develop a new class of MRI CAs that will be metal-free, safe, and completely eliminated from the human body after the MRI exam. The agents will consist of small endogenous molecules, in which nuclear spins will be hyperpolarised to ensure high sensitivity to MR detection, even at very low doses. A major challenge and risk arises from the rapid decay of the hyperpolarised (HP) state. As enabling technologies, AlternativesToGd focuses on three leading and innovative hyperpolarisation techniques and on unique agents showing HP state lifetimes that are sufficiently long to enable diagnostic contrast-enhanced MRI approaches with so far unobtained sensitivity.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

RIA - Research and Innovation action

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-FETOPEN-2018-2020

See all projects funded under this call

Coordinator

HADASSAH MEDICAL ORGANIZATION
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 440 870,00
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 440 870,00

Participants (9)

My booklet 0 0